Consistently, the recent reports from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) indicate that IL-1β inhibition with a monoclonal antibody (canakinumab) is effective in preventing MACEs among subjects with and without DM. Here, IL1B is linked to diabetes mellitus.